Skip to main content
logo
Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
12.28
-0.55 (-4.29%)
Sep 10, 2026, 4:00 PM EDT - Market closed

TNXP Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
29.113.1110.097.77--
Revenue Growth
196.02%29.85%29.94%---
Cost of Revenue
4.716.647.774.74--
Gross Profit
24.46.472.333.03--
Selling, General & Admin
125.9687.6840.134.7530.2223.47
Research & Development
63.8644.4939.9786.6681.8868.84
Operating Expenses
189.82132.1780.07121.41112.0992.31
Operating Income
-165.43-125.7-77.74-118.38-112.09-92.31
Interest Expense
-0.09-0.09-1.23---
Interest & Investment Income
5.354.150.02--0.03
Other Non Operating Income (Expenses)
0.5-0.287.881.721.87-
EBT Excluding Unusual Items
-159.67-121.93-71.08-116.66-110.22-92.29
Impairment of Goodwill
---1---
Asset Writedown
---57.96---
Other Unusual Items
--2.09----
Pretax Income
-159.67-124.02-130.04-116.66-110.22-92.29
Net Income
-159.67-124.02-130.04-116.66-110.22-92.29
Preferred Dividends & Other Adjustments
----6.66-
Net Income to Common
-159.67-124.02-130.04-116.66-116.88-92.29
Net Income Growth
------
Shares Outstanding (Basic)
1391---
Shares Outstanding (Diluted)
1391---
Shares Change
216.89%1055.90%----
EPS (Basic)
-12.49-14.57-176.60---
EPS (Diluted)
-12.49-14.57-176.60---
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-158.11-103.21-61.05-109.9-146.2-110.86
Free Cash Flow Per Share
-12.37-12.13-82.90---
Gross Margin
83.83%49.34%23.07%38.97%--
Operating Margin
-568.43%-959.05%-770.20%-1523.94%--
Profit Margin
-548.64%-946.22%-1288.25%-1501.78%--
Free Cash Flow Margin
-543.29%-787.47%-604.76%-1414.75%--
EBITDA
-163.3-123.78-74.32-114.09-110.84-92.26
D&A For EBITDA
2.121.933.424.291.250.05
EBIT
-165.43-125.7-77.74-118.38-112.09-92.31
SEC Filings: 10-K · 10-Q